30 closest matches · ranked by relevance
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions — 7 participants
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions (ADRs) — 2 Participants
Measles · Varicella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies Greater Than or Equal to (≥) the Cut-off Value. — 312; 157; 279; 142 Participants
Hepatitis A · Measles · Mumps
Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants
Measles; Mumps; Rubella; Chickenpox · Measles
Primary: GMC of Anti-measles Antibodies at Day 43 — 801; 788; 728; 682 mIU/mL
Measles Antibody Seroconversion · Rubella Antibody Seroconversion · Rotavirus Geometric Mean Titer (GMT)
Primary: Percentage/Number of Subjects With Seroprotection for Measles Virus Serum Neutralization Antibodies — 171; 173; 56; 60 Participants
Japanese Encephalitis
Primary: Number and Percentage of Subjects With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 14; 243; 233; 24 Participants
Japanese Encephalitis · Measles · Mumps
Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…
Measles; Mumps; Rubella · Measles-Mumps-Rubella Vaccine
Primary: Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination — 47; 17; 205; 95 Participants
Non-target Heterologous Effects of Vaccines · Vaccine Interactions
Primary: Effect on Interferon (IFN)-Gamma : Interleukin (IL)-4 Ratio in Plasma — 1.48; 1.44; 0.46 ratio of cytokines in pg/mL
Varicella · Chickenpox Vaccines
Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001
Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Dose Limiting Toxicity — 0; 0 participants with DLTs
Hepatitis A Virus
Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001
Rubella · Mumps · Measles
Primary: Anti-measles Virus Antibody Concentrations. — 1795.6; 1783.3 mIU/mL
Varicella · Rubella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies — 149; 153; 72; 149 Participants
Measles · Rubella · Rubella Syndrome, Congenital
Primary: Percent of Infants Who Were Seropositive After Immunization at 6 Months (Assessed at 9-month Visit) — 94; 94 percentage of infants
Encephalitis, Japanese · Measles · Mumps
Primary: Percentage of Participants With Measles Seropositivity 56 Days Post-vaccination — 98.1; 98.0 percentage of participants
Measles-Mumps-Rubella
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value — 697; 249; 736; 281 Participants
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Varicella Antibody Titer ≥5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL for Subjects Initially…
Measles · Mumps · Rubella
Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL — 97.3; 93.0 Percentage of participants — p=<0.001
Rubella · Mumps · Measles
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value. — 245; 236; 236; 248 Subjects
Encephalitis, Japanese B
Primary: Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination — 1.1; 0.0; 0.0; 88.6 percentage of participants
Measles · Mumps · Rubella
Primary: Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by Enzyme-linked Immunosorbent Assay [ELISA]) — 90.9; 94.3…
Prophylaxis for the Measles Infection
Primary: Incidence of Solicited Reactions — 0; 0; 0 participants
Measles · Varicella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Zoster Virus (VZV) Antibodies Above the Cut-off Values — 294; 155; 262; 145 Participants…
Multiple Myeloma
Primary: The Effectiveness of MV-NIS Therapy as Measured by the International Myeloma Working Group (IMWG) Guidelines
Sepsis Syndrome
Primary: Induction of MDSCs — 0.19; 0.11 fold change compared to baseline
Meningococcal Meningitis · Measles · Mumps
Primary: Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only) — 98; 98; 95; 95 Percentage of Participants
Rubella · Varicella · Measles
Primary: Number of Seroconverted Subjects for Measles, Mumps, Rubella, and Varicella Virus — 305; 162; 292; 151 Participants
Hepatitis A
Primary: Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. — 1390.4; 1895.2 mIU/mL